Fox Chase Cancer Center (FCCC) established biospecimen banking activities in 1987 to coordinate the ethical collection, storage, annotation, and distribution of tissue and peripheral blood samples to support translational research. This centralized, Center-wide activity is under the supervision of Boyd (Leader, Women's Cancer (WC) Program) within the Department of Pathology, and is overseen by an interprogrammatic Facility Advisory Committee (FAC). The Biosample Repository Facility (BRF) is a College of American Pathologists (CAP)-accrediled and CLIA-certified Facility that has two major functions: 1) identify participants, obtain informed consent, collect tissue, blood, and/or urine samples from selected populations, and obtain information on personal and family histories of cancer, clinical intervention, and lifestyle factors for use in research;and 2) process and store human biospecimens obtained through investigator-initiated studies. Working in collaboration with pathologists, medical oncologists, surgeons and other hospital personnel, specially trained BRF staff obtain subject informed consent, collect samples, and assemble comprehensive clinical, pathological, and personal/demographic information about each donor and the corresponding samples. As part of this banking process, the BRF staff provides: 1) outstanding diagnostic pathology support;2) a comprehensive informed consent process for the appropriate use of tissue, blood, and other biospecimens for research;3) a specialized biospecimen bank devoted to the collection and distribution of specimens to support research;and 4) extensive supporting data from the clinical record and self-reported health history of each participant. All specimens are linked to comprehensive clinical databases supported by the Population Studies Facility (PSF). The BRF currently houses over 11,000 fresh-frozen tissue samples, over 29,000 blood samples, and has access to >100,000 surgical pathology cases. The BRF has served 26 FCCC investigators (24 peer-reviewed, funded in CY 2009) across all five CCSG Programs. Ninety-six percent (96%) of the BRF's CY, 2009 use is by peer-reviewed, funded investigators. (See usage table Section V).
Translational research requires ready access to a robust and thoroughly annotated collection of human biosamples, obtained through a process of appropriate informed consent. Thus, a centralized Facility such as the BRF is essential to the research mission of a comprehensive cancer center such as the FCCC.
|Austin, Steven R; Wong, Yu-Ning; Uzzo, Robert G et al. (2015) Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work. Med Care 53:e65-72|
|Bassi, Daniel E; Cenna, Jonathan; Zhang, Jirong et al. (2015) Enhanced aggressiveness of benzopyrene-induced squamous carcinomas in transgenic mice overexpressing the proprotein convertase PACE4 (PCSK6). Mol Carcinog 54:1122-31|
|Sherman, Kerry A; Miller, Suzanne M; Roussi, Pagona et al. (2015) Factors predicting adherence to risk management behaviors of women at increased risk for developing lymphedema. Support Care Cancer 23:61-9|
|Eytan, Esther; Wang, Kexi; Miniowitz-Shemtov, Shirly et al. (2014) Disassembly of mitotic checkpoint complexes by the joint action of the AAA-ATPase TRIP13 and p31(comet). Proc Natl Acad Sci U S A 111:12019-24|
|Johnson, Matthew E; Handorf, Elizabeth A; Martin, Jeffrey M et al. (2014) Postmastectomy radiation therapy for T3N0: a SEER analysis. Cancer 120:3569-74|
|Gabitova, Linara; Gorin, Andrey; Astsaturov, Igor (2014) Molecular pathways: sterols and receptor signaling in cancer. Clin Cancer Res 20:28-34|
|Silverman, Diana; Ruth, Karen; Sigurdson, Elin R et al. (2014) Skin involvement and breast cancer: are T4b lesions of all sizes created equal? J Am Coll Surg 219:534-44|
|Gupta, Sapna; Melnyk, Stepan B; Kruger, Warren D (2014) Cystathionine *-synthase-deficient mice thrive on a low-methionine diet. FASEB J 28:781-90|
|Simhan, Jay; Smaldone, Marc C; Egleston, Brian L et al. (2014) Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma. BJU Int 114:216-20|
|Gowrishankar, Banumathy; Ibragimova, Ilsiya; Zhou, Yan et al. (2014) MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther 15:329-41|
Showing the most recent 10 out of 475 publications